Results 91 to 100 of about 16,563 (220)

Breast Skin Lesions in a 79‐Year‐Old Woman

open access: yes
JEADV Clinical Practice, EarlyView.
Javier Lorenz‐Dolz   +4 more
wiley   +1 more source

Daraxonrasib and Beyond: Pan‐RAS Inhibition, Resistance, and Next‐Generation Strategies

open access: yesCancer Science, EarlyView.
ABSTRACT RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins.
Ryo Honda
wiley   +1 more source

Phototherapies mediated by metallic nanoparticles and near‐infrared radiation in skin cancer: A systematic review

open access: yesPhotochemistry and Photobiology, EarlyView.
Recent studies demonstrate that near‐infrared (NIR—750–980 nm)‐mediated photodynamic (PDT) and photothermal (PTT) therapies, combined with metallic nanoparticles (MNPs), show promising results against skin cancer, particularly melanoma, in both in vitro and in vivo models.
Tamyris Devincenzi   +3 more
wiley   +1 more source

Identification of Novel Therapeutic Agent Candidates Through High Throughput Screening With Chemical Library Based on Molecular Subclassification in Canine Histiocytic Sarcoma Cell Lines

open access: yesVeterinary and Comparative Oncology, EarlyView.
ABSTRACT Effective chemotherapy for canine histiocytic sarcoma (CHS) has yet to be established. In our previous study, CHS cell lines were subclassified into two groups based on their gene expression profiles: Group A and Group B. This study aimed to identify novel therapeutic agents that are effective against each CHS subgroup, and we performed high ...
Hiroki Sakuma   +6 more
wiley   +1 more source

The role of extracellular vesicles in cell–cell crosstalk in cardiotoxicity

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Administration of a pharmacological agent can result in off‐target cardiotoxicity which can be driven by cell–cell crosstalk between healthy and dysfunctional cardiac cells. Extracellular vesicles (EVs) are lipid bilayer structures that can move biological cargo between cells, facilitating cell–cell crosstalk.
Gabriella Bachynskyj‐Bilas   +5 more
wiley   +1 more source

Pancreatic Cancer—Advances in the Last 50 Years

open access: yes
World Journal of Surgery, EarlyView.
S. George Barreto   +5 more
wiley   +1 more source

Small‐Bowel Impaction Caused by Mechanical Interlocking Between Duodenal Metal and Biliary Plastic Stents

open access: yesDEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Duodenal self‐expandable metal stents (SEMS) are widely used to treat malignant gastric outlet obstruction (GOO). However, stent migration is a well‐known complication. We report a rare case of small‐bowel impaction caused by the migration of a duodenal SEMS with a biliary plastic stent (PS).
Shinsuke Otagiri   +9 more
wiley   +1 more source

Comparison of Efficacy Between Nab-Paclitaxel or Docetaxel Combined with Carboplatin as Neoadjuvant Therapy for HER2-Positive Breast Cancer

open access: yesZhongliu Fangzhi Yanjiu
ObjectiveTo compare the efficacy of trastuzumab plus pertuzumab (HP) combined with either nab-paclitaxel plus carboplatin or docetaxel plus carboplatin as neoadjuvant therapy for HER2-positive breast cancer in real-world clinical practice ...
Xin HAO   +4 more
doaj   +1 more source

Transpapillary Placement of a Multihole Covered Metal Stent Using a 5.9‐Fr Delivery System Through a Forward‐viewing Endoscope in Malignant Biliary Obstruction With Type I Duodenal Stenosis

open access: yesDEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Concurrent malignant biliary obstruction (MBO) and type I duodenal stenosis represent a technically demanding scenario, as luminal narrowing frequently precludes passage of a standard side‐viewing duodenoscope and limits conventional transpapillary drainage.
Kengo Matsumoto   +8 more
wiley   +1 more source

Efficacy and safety of albumin-bound paclitaxel combined with simvastatin in the second-line treatment of small cell lung cancer: a phase II randomized controlled trial

open access: yesBMC Medicine
Background Small-cell lung cancer (SCLC) responds to first-line therapy, but most patients rapidly develop resistance. This study aimed to investigate the efficacy and safety of nab-paclitaxel combined with simvastatin as second-line treatment for SCLC ...
Maoying Guan   +15 more
doaj   +1 more source

Home - About - Disclaimer - Privacy